Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Dec 30;28(1):438.
doi: 10.1186/s13054-024-05214-5.

High rates of cefiderocol plasma target attainment: results of a retrospective cohort study in 31 critically ill ICU patients

Hans Theodor Naumann #  1   2 , Rainer Höhl #  1 , Martina Kinzig  3 , Sophie Salat  4 , Vanessa Bartsch  4 , Fritz Sörgel  3   5 , Ralph Bertram  6 , Joerg Steinmann  7 ; Therapeutic Drug Monitoring study group
Collaborators, Affiliations

High rates of cefiderocol plasma target attainment: results of a retrospective cohort study in 31 critically ill ICU patients

Hans Theodor Naumann et al. Crit Care. .

Erratum in

No abstract available

Keywords: Antibiotics; Antiinfectives; Cefiderocol; Pharmacodynamics; Pharmacokinetics; Therapeutic drug monitoring.

PubMed Disclaimer

Conflict of interest statement

Declarations. Ethics approval and consent to participate: This study was approved by the institutional review board at Klinikum Nürnberg (IRB-2024–15). Competing interests: RH was active in the Advisory Board of Shionogi, the supplier of cefiderocol. JS received speaker’s honorarium from Gilead, Pfizer and bioMérieux.

Figures

Fig. 1
Fig. 1
A Cmin values of the study cohort. Each symbol of the scatter plot represents one Cmin level. The bold and broader lines within the plots represent the median, the thinner and shorter lines denote the 25th and 75th percentiles. The fine line marks the target of 8 µg/mL of cefiderocol corresponding to four-fold MIC for relevant bacteria according to EUCAST. B relation between daily dose and measured plasma concentration. Each symbol represents one Cmin level. The fine line marks the target of 8 µg/mL of cefiderocol. The solid line shows a simple linear regression of daily dosage vs. Cmin with dotted lines showing the 95% confidence intervals. C and D Spaghetti-plots to illustrate dynamics in dose adjustment on plasma concentration in two sub-cohorts. Each pair of symbols represents one patient. Error bars are present in case of more than one level for the respective condition. C five patients with a dose reduction scheme from 6000 to 3000 mg per day, D five other patients with a dose reduction scheme from 6000 to 3000 mg per day. The fine line marks the target of 8 µg/mL of cefiderocol
See this image and copyright information in PMC

References

    1. Ito A, Sato T, Ota M, Takemura M, Nishikawa T, Toba S, et al. In vitro antibacterial properties of cefiderocol, a novel siderophore cephalosporin, against gram-negative bacteria. Antimicrob Agents Chemother. 2018;62(1):10–1128. - PMC - PubMed
    1. Katsube T, Echols R, Wajima T. Pharmacokinetic and pharmacodynamic profiles of cefiderocol, a novel siderophore cephalosporin. Clin Infect Dis. 2019;69(7):S552–8. - PMC - PubMed
    1. König C, Both A, Rohde H, Kluge S, Frey OR, Röhr AC, et al. Cefiderocol in critically ill patients with multi-drug resistant pathogens: real-life data on pharmacokinetics and microbiological surveillance. Antibiotics (Basel). 2021;10(6):649. - PMC - PubMed
    1. Kawaguchi N, Katsube T, Echols R, Wajima T. Population pharmacokinetic and pharmacokinetic/pharmacodynamic analyses of cefiderocol, a parenteral siderophore cephalosporin, in patients with pneumonia, bloodstream infection/sepsis, or complicated urinary tract infection. Antimicrob Agents Chemother. 2021;65(3):10–1128. - PMC - PubMed
    1. Gatti M, Bartoletti M, Cojutti PG, Gaibani P, Conti M, Giannella M, et al. A descriptive case series of pharmacokinetic/pharmacodynamic target attainment and microbiological outcome in critically ill patients with documented severe extensively drug-resistant acinetobacter baumannii bloodstream infection and/or ventilator-associated pneumonia treated with cefiderocol. J Glob Antimicrob Resist. 2021;27:294–8. - PubMed

LinkOut - more resources